Olanzapine plus venlafaxine in treatment-resistant depression.
S
S
Devarajan
S M
SM
Dursun
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D000077152:Olanzapine; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D003511:Cyclohexanols; D001569:Benzodiazepines; D000069470:Venlafaxine Hydrochloride; D000077152:Olanzapine